GC Biopharma secures a contract fee of 2,868hundred million won and an advance payment of 2,900hundred million won
GC Biopharma 7month 10day received a contract fee of 2,868hundred million won related to Eli Lilly and received early an advance payment of 2,900hundred million won from the sale of Curevo in the United States, increasing its cash holdings. On the same day, it signed a contract with Korea Vaccine for cooperation in contract manufacturing of vaccines.
GC Biopharma disclosed that it received a contract fee of 7month 10day from Eli Lilly totaling 2,868hundred million won. It said it had secured an early advance payment of 2,900hundred million won related to the sale of Curevo in the United States on the same day.
The company explained that the receipt dates for the contract fee and advance payment had been brought forward. The disclosure stated that the related amounts would be treated as separate items, respectively.
GC Biopharma and Korea Vaccine signed a strategic partnership focused on cooperation in contract manufacturing of vaccines on 7month 10day. The companies said they defined the scope of cooperation as contract manufacturing of vaccines (contract development and manufacturing).
The Air Force announced that E-737 airborne control aircraft extended its mission time to twice its previous duration through aerial refueling training. It explained that the training increased tactical operating time.
Meanwhile, the person in the relevant age group who spread false information 50was transferred under arrest on suspicion of disseminating false claims about the murder and sexual assault of a member of the National Assembly. The relevant agency said the case remains under investigation.
The foregoing are 7 month 10 day’s major disclosures and facts related to the government, military, and judiciary. Additional disclosures can be confirmed through the company’s electronic disclosures and announcements by relevant agencies.